Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$61.03 - $69.57 $3,295 - $3,756
54 New
54 $3,000
Q2 2023

Aug 07, 2023

BUY
$69.91 - $75.81 $8,529 - $9,248
122 New
122 $8,000
Q1 2023

May 08, 2023

SELL
$63.15 - $71.6 $5,557 - $6,300
-88 Closed
0 $0
Q4 2022

Feb 09, 2023

BUY
$54.21 - $70.44 $4,770 - $6,198
88 New
88 $5,000
Q2 2022

Aug 02, 2022

BUY
$59.26 - $71.14 $8,651 - $10,386
146 New
146 $10,000
Q3 2021

Nov 08, 2021

SELL
$55.56 - $60.79 $31,113 - $34,042
-560 Closed
0 $0
Q2 2021

Aug 10, 2021

SELL
$48.42 - $60.18 $24,210 - $30,090
-500 Reduced 47.17%
560 $34,000
Q1 2021

May 13, 2021

SELL
$47.16 - $54.44 $613 - $707
-13 Reduced 1.21%
1,060 $53,000
Q4 2020

Feb 09, 2021

BUY
$48.52 - $58.02 $630 - $754
13 Added 1.23%
1,073 $54,000
Q2 2020

Aug 10, 2020

SELL
$43.1 - $55.31 $18,274 - $23,451
-424 Reduced 28.57%
1,060 $56,000
Q1 2020

May 07, 2020

SELL
$37.79 - $51.33 $37,790 - $51,330
-1,000 Reduced 40.26%
1,484 $66,000
Q4 2019

Feb 14, 2020

BUY
$42.46 - $50.46 $81,141 - $96,429
1,911 Added 333.51%
2,484 $124,000
Q3 2019

Nov 13, 2019

BUY
$40.12 - $45.47 $3,570 - $4,046
89 Added 18.39%
573 $25,000
Q1 2019

May 13, 2019

SELL
$35.49 - $43.02 $7,985 - $9,679
-225 Reduced 31.73%
484 $20,000
Q3 2018

Nov 09, 2018

SELL
$34.76 - $39.72 $34,099 - $38,965
-981 Reduced 58.05%
709 $28,000
Q2 2018

Jul 26, 2018

SELL
$34.55 - $37.05 $83,576 - $89,623
-2,419 Reduced 58.87%
1,690 $59,000
Q1 2018

May 01, 2018

BUY
$32.97 - $36.63 $86,546 - $96,153
2,625 Added 176.89%
4,109 $144,000
Q4 2017

Feb 01, 2018

SELL
$32.09 - $34.78 $62,415 - $67,647
-1,945 Reduced 56.72%
1,484 $51,000
Q3 2017

Nov 08, 2017

BUY
$28.96 - $34.0 $99,303 - $116,586
3,429
3,429 $116,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Plante Moran Financial Advisors, LLC Portfolio

Follow Plante Moran Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Plante Moran Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Plante Moran Financial Advisors, LLC with notifications on news.